tau
Despite Leqembi's initial slow sales, the firm's CEO cited areas for the drug's growth and ambitions for an antisense oligonucleotide candidate targeting tau.
Despite Leqembi's initial slow sales, the firm's CEO cited areas for the drug's growth and ambitions for an antisense oligonucleotide candidate targeting tau.